Inference of mutability landscapes of tumors from single cell sequencing data.

PLoS Comput Biol

Department of Computer Science, Georgia State University, Atlanta, Georgia, United States of America.

Published: November 2020

One of the hallmarks of cancer is the extremely high mutability and genetic instability of tumor cells. Inherent heterogeneity of intra-tumor populations manifests itself in high variability of clone instability rates. Analogously to fitness landscapes, the instability rates of clonal populations form their mutability landscapes. Here, we present MULAN (MUtability LANdscape inference), a maximum-likelihood computational framework for inference of mutation rates of individual cancer subclones using single-cell sequencing data. It utilizes the partial information about the orders of mutation events provided by cancer mutation trees and extends it by inferring full evolutionary history and mutability landscape of a tumor. Evaluation of mutation rates on the level of subclones rather than individual genes allows to capture the effects of genomic interactions and epistasis. We estimate the accuracy of our approach and demonstrate that it can be used to study the evolution of genetic instability and infer tumor evolutionary history from experimental data. MULAN is available at https://github.com/compbel/MULAN.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728263PMC
http://dx.doi.org/10.1371/journal.pcbi.1008454DOI Listing

Publication Analysis

Top Keywords

mutability landscapes
8
sequencing data
8
genetic instability
8
instability rates
8
mutability landscape
8
mutation rates
8
evolutionary history
8
inference mutability
4
landscapes tumors
4
tumors single
4

Similar Publications

8-oxoguanine (8-oxoG) is a common oxidative DNA lesion that causes G > T substitutions. Determinants of local and regional differences in 8-oxoG-induced mutability across genomes are currently unknown. Here, we show DNA oxidation induces G > T substitutions and insertion/deletion (INDEL) mutations in human cells and cancers.

View Article and Find Full Text PDF

Background: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. Early detection via routine CRC screening can significantly lower risks for CRC-specific morbidity and mortality. Public health initiatives between 2000 and 2015 nearly doubled CRC screening rates for some US adults.

View Article and Find Full Text PDF

Rational mutagenesis of an epoxide hydrolase and its structural mechanism for the enantioselectivity improvement toward chiral ortho-fluorostyrene oxide.

Int J Biol Macromol

December 2024

School of Pharmacy & School of Biological and Food Engineering, Changzhou University, Changzhou 213164, PR China. Electronic address:

Chiral (S)-o-fluorostyrene oxide (oFSO) and vicinal diol (R)-o-fluorophenylethane-1,2-diol (oFPED) are important intermediates for synthesizing treatments for neuropathic diseases. This study aimed to engineer Aspergillus usamii epoxide hydrolase (AuEH2) through a rational mutagenesis strategy to customize high enantioselectivity mutant for rac-oFSO. Out of 181 single-site mutants screened, six showed elevated enantiomeric ratio (E value) ranging from 32 to 108 according to E value and activity mutability landscapes.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores how different COVID-19 booster vaccinations and recovery from Omicron BA.5 infections affect the body's ability to neutralize various Omicron sublineages.
  • Bivalent booster recipients showed significantly better neutralization abilities against specific Omicron variants compared to monovalent booster recipients, while individuals recovered from BA.5 had similar neutralizing antibody levels to bivalent recipients.
  • Despite enhanced responses, there were limitations in neutralization against newer subvariants, highlighting the necessity for potentially updated vaccines to tackle these evolving strains.
View Article and Find Full Text PDF

A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.

Cell Rep Med

September 2024

Departments of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address:

Activating EGFR (epidermal growth factor receptor) mutations can be inhibited by specific tyrosine kinase inhibitors (TKIs), which have changed the landscape of lung cancer therapy. However, due to secondary mutations and bypass receptors, such as AXL (AXL receptor tyrosine kinase), drug resistance eventually emerges in most patients treated with the first-, second-, or third-generation TKIs (e.g.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!